Fiche centre
University Hospitals Plymouth NHS Trust
Plymouth — United Kingdom
Essais liés7clinical trials
VillePlymouthlocalisation
PaysUnited Kingdomlocalisation
SourcelocaleCSV/MySQL
Informations
centreSynchronisé depuis ClinicalTrials.gov — NCT05819359
Essais cliniques associés
7| Molécule | Indication / population | Phase | NCT | Titre | Statut |
|---|---|---|---|---|---|
| Computed tomography coronary angiography (CTCA) | Maladie coronarienne | À vérifier | NCT06234410 | CRAFT-CTCA — Cardiovascular Risk Assessment For Kidney Transplantation - Utility of Computed Tomography Coronary Angiography in the Assessment of Patients Awaiting Kidney Transplantation | RECRUITING |
| BIA 28-6156 10 mg | Parkinson | Phase 2 | NCT05819359 | ACTIVATE — Efficacy, Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of BIA 28-6156 in GBA-PD | COMPLETED |
| 1ml of triamcinolone (40mg/1ml) | Myopathies | Phase 3 | NCT04253457 | The SToICAL Study - The Soft Tissue Injection of Corticosteroid And Local Anaesthetic Study | TERMINATED |
| Cladribine (MAVENCLAD®) | SEP | Phase 2/3 | NCT04695080 | ChariotMS - Cladribine to Halt Deterioration in People With Advanced Multiple Sclerosis | ACTIVE_NOT_RECRUITING |
| RAP-219 | Épilepsie | Phase 3 | NCT07563881 | FOCUS 1 — Study Evaluating the Efficacy and Safety of RAP-219 in Adult Participants With Focal Seizures FOCUS-1 | RECRUITING |
| BIA 28-6156 | Parkinson | À vérifier | NCT07522606 | Compassionate Use for BIA 28-6156 in Patients With Parkinson's Disease (PD) Who Have a Pathogenic Variant in the GBA1 Gene (GBA-PD) and Completed the ACTIVATE Study | NO_LONGER_AVAILABLE |
| CVN424 75 mg | Parkinson | Phase 3 | NCT06553027 | To Evaluate the Efficacy of CVN424 in Parkinson's Disease Participants With Motor Complications | ACTIVE_NOT_RECRUITING |